Variant Summary
- HGVS
- —
- Variant Type(s)
- protein_altering_variant
- Evidence Items
- 27
Evidence Level Distribution
Level A: 1Level B: 22Level C: 2Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = TP53 and variant = Mutation.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 5 | |
| B | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 5 | |
| A | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 5 | |
| B | Prognostic | Supports | Lung Non-small Cell Carcinoma | 5 | ||
| B | Prognostic | Supports | Poor Outcome | Medulloblastoma SHH Activated | 5 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Myelodysplastic Syndrome | Azacitidine,Eprenetapopt | 4 |
| B | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Esophagus Squamous Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | B-lymphoblastic Leukemia/lymphoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Myelodysplastic Syndrome | 4 | |
| B | Prognostic | Supports | Poor Outcome | Myeloid Neoplasm | 4 | |
| B | Prognostic | Does Not Support | Poor Outcome | Head And Neck Squamous Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Head And Neck Squamous Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | B-lymphoblastic Leukemia/lymphoma | 4 | |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Doxorubicin | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Selumetinib,Docetaxel | 3 |
| B | Predictive | Supports | Sensitivity/Response | Cancer | VEGF/VEGFR Inhibitors | 3 |
| B | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 3 | |
| B | Prognostic | Supports | Poor Outcome | Chronic Lymphocytic Leukemia | 3 | |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 3 | |
| B | Prognostic | Does Not Support | Poor Outcome | Head And Neck Squamous Cell Carcinoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Gastric Adenocarcinoma | Chemotherapy | 3 |
| B | Prognostic | Supports | Poor Outcome | Adrenocortical Carcinoma | 2 | |
| B | Predictive | Supports | Sensitivity/Response | Chronic Lymphocytic Leukemia | Alemtuzumab | 2 |
| C | Predictive | Supports | Resistance | Breast Cancer | Tamoxifen | 1 |
| C | Predictive | Supports | Sensitivity/Response | Stomach Carcinoma | Cisplatin,Etoposide,Doxorubicin | 1 |